

The

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ruiz Caston et al.

Application No. 10/576,778

Filed: April 21, 2006 Confirmation No. 6010

Essa DD

PROCESS FOR PRODUCING IN YEASTS EMPTY VIRAL CAPSIDS CONSISTING

OF PROTEINS DERIVED FROM PVP2 OF THE INFECTIOUS BURSAL DISEASE

VIRUS (IBDV)

Examiner: Not yet assigned

Art Unit: 1642

Attorney Reference No. 7572-74819-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on the date indicated below as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Sheree Lynn Rybak, Ph.D. Attorney for Applicants

Date of Deposit: March 7, 2007

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. The relevance of the non-English-language documents can be ascertained from the English-language abstract attached to each non-English-language document. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Registration No. 47,913

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc: Docketing

MAR 0 9 2007

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of Copies

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0165176	November 7, 2002	HAYNES et al.
		2003/0152592	August 14, 2003	BOOT et al.
		2003/0175301	September 18, 2003	COHEN et al.
		2004/0005338	January 8, 2004	BACHMANN et al.
		2004/0116664	June 17, 2004	DE FILETTE et al.
		2004/0223976	November 11, 2004	BIANCHI et al.
		2005/0003349	January 6, 2005	KAWAOKA
		2005/0009008	January 13, 2005	ROBINSON et al.
•		2005/0186621	August 25, 2005	GALARZA et al.
		2006/0024670	February 2, 2006	LUKE et al.
		2006/0251623	November 9, 2006	BACHMANN et al.
		2006/0121468	June 8, 2006	ALLNUTT et al.
		2006/0121567	June 8, 2006	VAKHARIA
		5,290,686	March 1, 1994	KENDAL et al.
		5,605,827	February 25, 1997	JACKWOOD et al.
		5,605,792	February 25, 1997	JACKWOOD et al.
		5,614,409	March 25, 1997	AZAD et al.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
RV APPLICANT

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date -	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

 		1100 900 400181104
5,616,327	April 1, 1997	JUDD et al.
5,641,490	June 24, 1997	PAOLETTI et al.
5,658,572	August 19, 1997	PAOLETTI et al.
5,788,970	August 4, 1998	VAKHARIA et al.
5,871,744	February 16, 1999	VAKHARIA et al.
5,916,879	June 29, 1999	WEBSTER
5,932,426	August 3, 1999	BARALLE et al.
6,017,759	January 25, 2000	VAKHARIA et al.
6,114,112	September 5, 2000	JACKWOOD
6,156,314	December 5, 2000	VAKHARIA et al.
6,169,175	January 2, 2001	FRACE et al.
6,231,868	May 15, 2001	VAKHARIA et al.
6,274,147	August 14, 2001	VAKHARIA et al.
6,406,843	June 18, 2002	SKEELES and NEWBERRY
6,458,362	October 1, 2002	CASAL et al.
6,528,063	March 4, 2003	STRAM et al.
6,596,280	July 22, 2003	VAKHARIA et al.
6,602,705	August 5, 2003	BARNETT et al.
6,764,684	July 20, 2004	SAITOH et al.
6,872,395	March 29, 2005	KAWAOKA

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

6,936,256	August 30, 2005	VAKHARIA
6,964,769	November 15, 2005	SEBBEL et al.
7,022,327	April 4, 2006	LÜTTICKEN et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 861 665 A1	September 2, 1998	Dimminaco AG/SA/LTD.
		EPC	EP 0 887 412 B1	December 30, 1998	Akzo Nobel NV
		EPC	EP 1 069 187 A1	January 17, 2001	Stichting Dienst Landbouwkundig Onderzoeck
		EPC	EP 1 621 612 A1	February 1, 2006	Bionostra, S.L. and Consejo Superior de Investigaciones Científicas
		Japan	5194597A	August 3, 1993	Nippon Seibutsu Kagaku Kenkyus
		WIPO	WO 93/03145 A1	February 18, 1993	Virogenetics Corporation
		WIPO	WO 95/26196 A1	October 5, 1995	The University of Maryland College Park
		WIPO	WO 98/09646 A1	March 12, 1998	University of Maryland Biotechnology Institute
		WIPO	WO 98/33522 A1	August 6, 1998	Dimminaco AG
		WIPO	WO 98/50071 A1	November 12, 1998	Chiron Corporation
		WIPO	WO 99/16866 A1	April 8, 1999	University of Maryland Biotechnology Institute
		WIPO	WO 00/37649 A2	June 29, 2000	University of Maryland Biotechnology Institute
		WIPO	WO 01/97839 A1	December 27, 2001	Meristem
		WIPO	WO 02/00885 A2	January 3, 2002	American Cyanamid Company
EXAMINE	R			DATE	

SIGNATURE:

CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SLR/dm 03/05/07 7572-74819-01 (36515 P1148PC00			
		Attorney Docket N	umber	7572-74819-01
		Application Number	er	10/576,778
INFORMATION DISC	Filing Date	Filing Date		
BY APP	BY APPLICANT			Caston
		Art Unit	Art Unit	
		Examiner Name		Not yet assigned
WIPO	WO 02/088339 A2	November 7, 2002	Institu	t National de la
			Reche	rche Agronomique
			(INRA	
WIPO	WO 02/096940 A2	December 5, 2002		lystad, Institut Voor
				ouderij En
WIPO	WO 03/013597 A1	Fahruary 20, 2002		ezondheid B.V.
WIFO	WO 03/013397 A1	February 20, 2003	1	rsity of Maryland chnology Institute
WIPO	WO 03/024480 A2	March 27, 2003		Biotechnology AG
	0 00, 02 1 100 112	17741011 27, 2003	Cytos	Biotocimiology 11G
WIPO	WO 03/024481 A2	March 27, 2003	Cytos	Biotechnology AG
WIPO	WO 03/074552 A1	September 12, 2003	Akzo	Nobel N.V.
WIPO	WO 2004/003143 A2	January 8, 2004	Allnut	t and Kyle
WIPO	WO 2004/007538 A2	January 22, 2004	Cytos	Biotechnology AG
WIPO	WO 2004/025263 A2	March 25, 2004	Advar	nced Bionutrition
			Corpo	
WIPO	WO 2004/087900 A1	October 14, 2004		jo Superior de
			Investigaciones Científicas and	
WIPO	WO 2005/040704 A2	June 2, 2005		stra, S.L.
WIPO	WO 2005/049794 A2	June 2, 2005		rsity of Georgia rch Foundation, Inc.
WIPO	WO 2005/071068 A1	August 4, 2005		jo Superior de
	3 2000/071000711	1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		igaciones Científicas and
			1	stra, S.L.
WIPO	WO 2005/071069 A1	August 4, 2005		jo Superior de
				igaciones Científicas and
				stra, S.L.
WIPO	WO 2006/027698 A1	March 16, 2006	Chiron	n Behring Gmbh & Co.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

March 30, 2006

WO 2006/032674 A1

WIPO

Cytos Biotechnology AG

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		BIRGHAN <i>et al.</i> , "A non-canonical lon proteinase lacking the ATPase domain employs the Ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus," <i>Embo J.</i> , 19:114-123, 2000.
		BÖTTCHER <i>et al.</i> , "Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy," <i>J. Virol.</i> , 71:325-330, 1997.
		CASTÓN et al., "C terminus of infectious bursal disease virus major capsid protein VP2 is involved in definition of the T number for capsid assembly," J. Virol., 75:10815-10828, 2001.
		CHEVALIER <i>et al.</i> , "The maturation process of pVP2 requires assembly of infectious bursal disease virus capsids," <i>J. Virol.</i> , 76:2384-2392, 2002.
		CHEVALIER et al., "The last C-terminal residue of VP3, glutamic acid 257, controls capsid assembly of infectious bursal disease virus," J. Virol., 78:3296–3303, 2004.
		CHUNG et al., "Sequence analysis of the bicistronic Drosophila X virus genome segment A and its encoded polypeptides," Virology, 225:359-368, 1996.
		DA COSTA <i>et al.</i> , "The capsid of infectious bursal disease virus contains several small peptides arising from the maturation process of pVP2," <i>J. Virol.</i> , 76:2393-2402, 2002.
		DA COSTA <i>et al.</i> , "Blotched snakehead virus is a new aquatic birnavirus that is slightly more related to avibirnavirus than to aquabirnavirus," <i>J. Virol.</i> , 77:719-725, 2003.
		FERNÁNDEZ-ARIAS <i>et al.</i> , "Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles," <i>J. Gen. Virol.</i> , 79:1047-1054, 1998.
		FERNÁNDEZ-ARIAS <i>et al.</i> , "The major antigenic protein of infectious bursal disease virus, VP2, is an apoptotic inducer," <i>J. Virol.</i> , 71:8014-8018, 1997.
		GALARZA et al., "Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge," Viral. Immunol., 18:365-372, 2005.
		HU et al., "Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography," Biotechnol. Bioeng., 63:721-729, 1999.
		HU and BENTLEY, "Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results," <i>Biotechnol. Bioeng.</i> 75:104-119, 2001.
		IONESCU <i>et al.</i> , "Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier," <i>J. Pharm. Sci.</i> , 95:70-79, 2006. JAGADISH <i>et al.</i> , "Expression and characterization of infectious bursal disease virus
		polyprotein in yeast," <i>Gene</i> , 95:179-186, 1990.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

 Examiner Name Not yet assigned
JEGERLEHNER et al., "Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity," J. Immunol. 172:5598-5605, 2004.
KADONO-OKUDA et al., "Baculovirus-mediated production of the human growth hormone in larvae of the silkworm, Bombyx mori." Biochem. Biophys. Res. Commun., 213:389-396, 1995.
KATAGIRI and INGHAM, "Enhanced production of green fluorescent fusion proteins in baculovirus expression system by addition of secretion signal," <i>Biotechniques</i> , 33:24-26, 2002.
KIBENGE et al., "Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells," Can. J. Vet. Res., 63:49-55, 1999.
KINGSMAN et al., "Yeast retrotransposon particles as antigen delivery systems," Ann. N. Y. Acad. Sci., 754:202-213, 1995.
KOCHAN et al., "Characterization of the RNA binding activity of VP3, a major structural protein of IBDV," Arch. Virol., 148:723-744, 2003.
LEJAL et al., "Role of Ser-652 and Lys-692 in the protease activity of infectious bursal disease virus VP4 and identification of its substrate cleavage sites," J. Gen. Virol., 81:983-992, 2000.
LEONG et al. (Eds.), "Virus TaxonomyThe Classification and Nomenclature of Viruses: Seventh Report of International Committee on Taxonomy of Viruses," Academic Press, San Diego, pp. 481–490, 2000.
LEUSCH et al., "A novel host-vector system for direct selection of recombinant baculoviruses (bacmids) in Escherichia coli.," Gene, 160:191-194, 1995.
LO-MAN, et al., "A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Thl immune response without adjuvant," Eur. J. Immunol., 28:1401-1407, 1998.
LOMBARDO <i>et al.</i> , "VP1, the putative RNA-dependent RNA polymerase of infectious bursal disease virus, forms complexes with the capsid protein VP3, leading to efficient encapsidation into virus-like particles," <i>J. Virol.</i> , 73:6973-6983, 1999.
LOMBARDO <i>et al.</i> , "VP5, the nonstructural polypeptide of infectious bursal disease virus, accumulates within the host plasma membrane and induces cell lysis," <i>Virology</i> , 277:345-357, 2000.
LUCKOW et al., "Efficient generation of infectious recombinant baculoviruses by site-specific tranposon-mediated insertion of foreign genes into a baculovirus genome propagated in <i>Escherichia coli.</i> ," <i>J. Virol.</i> , 67:4566-4579, 1993.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

Examiner Name Not yet assigned	
MACREADIE et al., "Passive protection against infectious bursal disease virus by v	ral
VP2 expressed in yeast," Vaccine, 8:549-552, 1990.	
MARAVER et al., "Identification and molecular characterization of the RNA polym	erase-
binding motif of the inner capsid protein VP3 of infectious bursal disease virus," J. V	irol.,
77:2459-2468, 2003.	
MARAVER et al., "The Oligomerization Domain of VP3, the Scaffolding Protein of	
Infectious Bursal Disease Virus, Plays a Critical Role in Capsid Assembly," J. Virol.	,
77:6438–6449, 2003.	
MARTINEZ-TORRECUADRADA et al., "Different architectures in the assembly o	f
infectious bursal disease virus capsid protein expressed in insect cells," Virology,	
278:322-331, 2000.	
MARTÍNEZ-TORRECUADRADA et al., "Structure-dependent efficacy of infection	S
bursal disease virus (IBDV) recombinant vaccines," <i>Vaccine</i> , 21:3342-3350, 2003.	
OÑA et al., "The C-terminal domain of the pVP2 precursor is essential for the intera	ction
between VP2 and VP3, the capsid polypeptides of infectious bursal disease virus,"	
Virology, 322:135-142, 2004.	
PITCOVSKI et al., "Development and large-scale use of recombinant VP2 vaccine f	or the
prevention of infectious bursal disease of chickens," Vaccine, 21:4736-4743, 2003.	
POUS et al., "Structure of birnavirus-like particles determined by combined electron	
cryomicroscopy and X-ray crystallography," J. Gen. Virol., 86:2339–2346, 2005.	•
QIU et al., "Expression and characterization of virus-like particles containing rubella structural proteins," J. Virol., 68:4086-4091, 1994.	virus
RAZZINI et al., "Low-density lipoprotein (LDL) receptor/transferrin fusion protein:	:
vivo production and functional evaluation as a potential therapeutic tool for lowering	ın
plasma LDL cholesterol.," Hum. Gene Ther., 15:533-541, 2004.	
SÁNCHEZ and RODRÍGUEZ, "Proteolytic processing in infectious bursal disease v	irue
identification of the polyprotein cleavage sites by site-directed mutagenesis," Virolog	nus.
262:190-199, 1999.	у,
SCHMIDT et al., "Binding of external ligands onto an engineered virus capsid.," Pro	tein
Eng., 14:769-774, 2001.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SHARMA et al., "Infectious bursal disease virus of chickens: pathogenesis and	
immunosuppression," Dev. Comp. Immunol., 24:223-235, 2000.	
SHIN and FOLK, "Formation of polyomavirus-like particles with different infectious	3
bursal disease virus, plays a critical role for capsid formation," J. Virol., 77:11491-11	498,
2003.	
SHIVAPPA et al., "Development of a subunit vaccine for infectious pancreatic necro	
virus using a baculovirus insect/larvae system," Dev. Biol. (Basel), 121:165-174, 200	5

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE.	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SLR/dm	03/05/07	7572-74819-01	636515	P1148PC0
CI D/J	03/05/03	5550 54010 O.		D

Attorney Docket Number	7572-74819-01
Application Number	10/576,778
Filing Date	April 21, 2006
First Named Inventor	Caston
Art Unit	1642
Examiner Name	Not yet assigned

 Examiner Name Not yet assigned
TACKEN et al., "Interactions in vivo between the proteins of infectious bursal disease virus: capsid protein VP3 intereacts with the RNA-dependent RNA polymerase, VP1," J. Gen. Virol., 81:209-218, 2000.
VAKHARIA <i>et al.</i> , "Infectious bursal disease virus structural proteins expressed in a baculovirus recombinant confer protection in chickens," <i>J. Gen. Virol.</i> , 74:1201-1206, 1993.
VAKHARIA, "Development of recombinant vaccines against infectious bursal disease," <i>Biotechnol. Ann. Rev.</i> , 3:151-168, 1997.
VAN DEN BERG et al., "Infectious bursal disease (Gumboro disease)," Rev. Sci. Tech., 19:527-543, 2000.
VEENENDAAL et al., "In vitro and in vivo studies of a VEGF ₁₂₁ /rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors," Proc. Natl. Acad. Sci. U.S.A., 99:7866-7871, 2002.
WANG et al., "Self-assembly of the infectious bursal disease virus capsid protein, rVP2, expressed in insect cells and purification of immunogenic chimeric rVP2H particles by immobilized metal-ion affinity chromatography," Biotechnol. Bioeng. 67:104-111, 2000.
YAO and VAKHARIA, "Generation of infectious pancreatic necrosis virus from cloned cDNA," <i>J. Virol.</i> , 72:8913-8920, 1998.

	DATE CONSIDERED:
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.